MCID: TCL027
MIFTS: 51

T-Cell Acute Lymphoblastic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for T-Cell Acute Lymphoblastic Leukemia

MalaCards integrated aliases for T-Cell Acute Lymphoblastic Leukemia:

Name: T-Cell Acute Lymphoblastic Leukemia 12 36 29 6 15 17
Precursor T-Lymphoblastic Lymphoma/leukemia 12
Leukemia, Acute, Lymphoblastic, T-Cell 39
Leukemia, T-Cell Acute Lymphoblastic 39
Precursor T Lymphoblastic Leukemia 12
T-Cell Acute Lymphocytic Leukaemia 12
T Acute Lymphoblastic Leukemia 12
Acute T Cell Leukaemia 12
Leukemia, Acute T-Cell 39
Acute T Cell Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5603
KEGG 36 H00002
MeSH 43 D015459
NCIt 49 C3184
SNOMED-CT 67 110007008 77430005
ICD10 32 C91.5
UMLS 71 C0023493

Summaries for T-Cell Acute Lymphoblastic Leukemia

KEGG : 36 Acute lymphocytic leukemia (ALL) is a clonal stem cell malignancy of excessive lymphoblast proliferation. It is now understood that ALL and lymphoblastic lymphoma are the same disease entities at the morphologic and immunophenotypic levels and classified as either B- and T-cell lymphoblastic leukemia/lymphoma (B-ALL and T-ALL). T-ALL comprises 15% of paediatric and 25% of adult ALL cases. T cell transformation is a multi-step process in which different genetic alterations cooperate to alter the normal mechanisms that control cell growth, proliferation, survival, and differentiation during thymocyte development. In this context, constitutive activation of NOTCH1 signaling is the most prominent oncogenic pathway in T cell transformation. In addition, T-ALLs characteristically show the translocation and aberrant expression of transcription factor oncogenes. These oncogenic transcription factors include T-cell leukaemia homeobox protein 1 (TLX1 also known as HOX11), TLX3 (HOX11L2), LYL1, TAL1 and MLL.

MalaCards based summary : T-Cell Acute Lymphoblastic Leukemia, also known as precursor t-lymphoblastic lymphoma/leukemia, is related to precursor t-cell acute lymphoblastic leukemia and leukemia, acute lymphoblastic. An important gene associated with T-Cell Acute Lymphoblastic Leukemia is BAX (BCL2 Associated X, Apoptosis Regulator), and among its related pathways/superpathways are Transcriptional misregulation in cancer and NF-kappaB Signaling. The drugs Prednisone and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include t cells, myeloid and b cells, and related phenotypes are cellular and hematopoietic system

Related Diseases for T-Cell Acute Lymphoblastic Leukemia

Diseases related to T-Cell Acute Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 precursor t-cell acute lymphoblastic leukemia 35.2 TLX3 TLX1 TAL1 NUP98 NOTCH1 LYL1
2 leukemia, acute lymphoblastic 34.2 TLX1 TAL1 NOTCH1 NALT1 LMO2 IL2
3 leukemia 32.5 TLX3 TLX1 TAL2 TAL1 NUP98 NOTCH1
4 t-cell lymphoblastic leukemia/lymphoma 32.2 TLX1 TAL1 NOTCH1 LMO2 LMO1 LCK
5 lymphoblastic lymphoma 32.1 TLX1 TAL1 NOTCH1 LMO2 FBXW7
6 acute leukemia 32.0 TAL1 NUP98 NOTCH1 IL2
7 leukemia, acute myeloid 32.0 TAL1 NUP98 NOTCH1 LYL1 LMO2 LCK
8 lymphoma 31.7 TLX1 TAL1 NOTCH1 IL2 BCL10 BAX
9 severe combined immunodeficiency 31.5 NOTCH1 LMO2 LCK IL2
10 leukemia, chronic lymphocytic 31.3 NOTCH1 LCK IL2 BCL10 BAX ATM
11 lymphoma, non-hodgkin, familial 31.2 TAL1 NOTCH1 LCK IL2 BCL10 BAX
12 hematologic cancer 31.2 NUP98 NOTCH1 IL2 ATM ABL1
13 myelodysplastic syndrome 30.9 NUP98 NOTCH1 IL2 ATM ABL1
14 childhood t-cell acute lymphoblastic leukemia 12.9
15 refractory t lymphoblastic leukemia/lymphoma 11.8
16 t-cell adult acute lymphocytic leukemia 11.7
17 pdgfra-associated chronic eosinophilic leukemia 11.6
18 lymphosarcoma 11.6
19 leukemia, t-cell, chronic 10.8
20 leukemia, acute lymphoblastic 3 10.8
21 myeloid leukemia 10.7
22 breast liposarcoma 10.6 NOTCH1 IL2
23 interleukin-7 receptor alpha deficiency 10.6
24 combined t cell and b cell immunodeficiency 10.6 NOTCH1 LMO2 LCK IL2 ATM
25 adult acute lymphocytic leukemia 10.6
26 adenoiditis 10.6 NOTCH1 BCL10
27 b-cell lymphoma 10.5
28 glucocorticoid resistance, generalized 10.5
29 b-lymphoblastic leukemia/lymphoma with iamp21 10.5 TLX3 ABL1
30 ovarian serous cystadenocarcinoma 10.5 FBXW7 BAX ATM
31 leukemia, chronic myeloid 10.5
32 graft-versus-host disease 10.5
33 helix syndrome 10.5
34 childhood acute lymphocytic leukemia 10.5
35 ataxia-telangiectasia 10.4
36 lung disease, immunodeficiency, and chromosome breakage syndrome 10.4
37 adult t-cell leukemia 10.4
38 pancytopenia 10.4
39 telangiectasis 10.4
40 myeloproliferative neoplasm 10.4
41 acute kidney failure 10.4
42 chromosomal triplication 10.4
43 ataxia and polyneuropathy, adult-onset 10.3
44 wilms tumor 5 10.3
45 neutropenia 10.3
46 histiocytosis 10.3
47 47,xyy 10.3
48 acute graft versus host disease 10.3
49 splenomegaly 10.3
50 wilms tumor 1 10.3

Graphical network of the top 20 diseases related to T-Cell Acute Lymphoblastic Leukemia:



Diseases related to T-Cell Acute Lymphoblastic Leukemia

Symptoms & Phenotypes for T-Cell Acute Lymphoblastic Leukemia

MGI Mouse Phenotypes related to T-Cell Acute Lymphoblastic Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 ABL1 ATM BAX BCL10 FBXW7 IL2
2 hematopoietic system MP:0005397 10.21 ABL1 ATM BAX BCL10 FBXW7 IL2
3 immune system MP:0005387 10.17 ABL1 ATM BAX BCL10 FBXW7 IL2
4 embryo MP:0005380 10.1 ABL1 ATM BCL10 FBXW7 LCK LMO2
5 mortality/aging MP:0010768 10.1 ABL1 ATM BAX BCL10 FBXW7 IL2
6 nervous system MP:0003631 9.77 ABL1 ATM BAX BCL10 FBXW7 LMO2
7 neoplasm MP:0002006 9.76 ATM BAX FBXW7 IL2 LMO2 NOTCH1
8 respiratory system MP:0005388 9.17 ABL1 BAX FBXW7 IL2 NOTCH1 OLIG2

Drugs & Therapeutics for T-Cell Acute Lymphoblastic Leukemia

Drugs for T-Cell Acute Lymphoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
2
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
3
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
5
Vincristine Approved, Investigational Phase 2, Phase 3 57-22-7, 2068-78-2 5978
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7
Pegaspargase Approved, Investigational Phase 2, Phase 3 130167-69-0
8
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
9
Methotrexate Approved Phase 2, Phase 3 59-05-2, 1959-05-2 126941
10
Mercaptopurine Approved Phase 2, Phase 3 50-44-2 667490
11
Ichthammol Approved Phase 3 8029-68-3
12
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
13
Cytarabine Approved, Experimental, Investigational Phase 2, Phase 3 147-94-4, 65-46-3 6253
14
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
15
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
16
Daunorubicin Approved Phase 3 20830-81-3 30323
17
Thioguanine Approved Phase 3 154-42-7 2723601
18
Ifosfamide Approved Phase 3 3778-73-2 3690
19
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
20
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
21
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
22
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
23 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
24
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
25
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
26
Amsacrine Approved, Investigational Phase 2, Phase 3 51264-14-3 2179
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
28
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
29
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
30
Cortisone Experimental Phase 3 53-06-5 222786
31
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
32 Cardiotonic Agents Phase 3
33 razoxane Phase 3
34 Gastrointestinal Agents Phase 2, Phase 3
35 Antineoplastic Agents, Hormonal Phase 2, Phase 3
36 Hormones Phase 2, Phase 3
37 Antiemetics Phase 2, Phase 3
38 Hormone Antagonists Phase 2, Phase 3
39 glucocorticoids Phase 2, Phase 3
40 Anti-Inflammatory Agents Phase 2, Phase 3
41 Folic Acid Antagonists Phase 2, Phase 3
42 Immunosuppressive Agents Phase 2, Phase 3
43 Vitamin B Complex Phase 2, Phase 3
44 Alkylating Agents Phase 2, Phase 3
45 Folate Phase 2, Phase 3
46 Anti-Infective Agents Phase 2, Phase 3
47 Anti-Bacterial Agents Phase 3
48
Liposomal doxorubicin Phase 3 31703
49 Dermatologic Agents Phase 2, Phase 3
50 Immunologic Factors Phase 2, Phase 3

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
2 ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
3 AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3 dexamethasone;asparaginase;Asparaginase;cyclophosphamide;cytarabine;daunorubicin;doxorubicin;Etoposide;Ifosfamide;mercaptopurine;Methotrexate;prednisone;thioguanine;Vincristine;Vindesine
4 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) Active, not recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine;Vincristine Sulfate
5 Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
6 A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology Active, not recruiting NCT01228331 Phase 2, Phase 3 Amsacrine;Clofarabine;Cyclophosphamide;Cytarabine;Daunorubicin hydrochloride;Dexamethasone;Doxorubicin hydrochloride;Etoposide phosphate;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Thioguanine;Vincristine sulfate
7 A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients Completed NCT02518113 Phase 1, Phase 2 LY3039478;Dexamethasone;Placebo
8 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
9 A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-cell Acute Lymphoblastic Leukemia (ALL) Completed NCT00006020 Phase 2 nelarabine
10 A Phase II Study of 506U78 in Patients With Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphomas (LBL) Completed NCT00003545 Phase 2 nelarabine
11 A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia Completed NCT00077922 Phase 2 LMB-2
12 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
13 Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed NCT00866749 Phase 2 Daunorubicin;Vincristine;PEG-asparaginase;Intrathecal Methotrexate;Cyclophosphamide;Cytarabine;Mercaptopurine;Methotrexate;Doxorubicin;Thioguanine
14 Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma Recruiting NCT00501826 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine Sulfate
15 A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Recruiting NCT02763384 Phase 2 BL-8040;Nelarabine
16 A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia Recruiting NCT03575325 Phase 2 CPX-351
17 A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies Recruiting NCT04033302 Phase 1, Phase 2
18 An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting NCT03384654 Phase 2 Daratumumab;Vincristine;Prednisone;Doxorubicin;Cyclophosphamide;Cytarabine;6-mercaptopurine;Methotrexate
19 Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Recruiting NCT03808610 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine
20 Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse Recruiting NCT03860844 Phase 2 Montelukast;Isatuximab;Dexamethasone;Fludarabine;Cytarabine;Liposomal daunorubicin;Daunorubicin;Idarubicin;Filgrastim;Mitoxantrone;Doxorubicin;Vincristine;PEG Asparaginase;Cyclophosphamide;Etoposide;Methotrexate
21 Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies Recruiting NCT03983850 Phase 1, Phase 2 Busulfan;Fludarabine;Cyclophosphamide;Mycophenolate Mofetil;Sirolimus
22 A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) Not yet recruiting NCT04315324 Phase 2 AKR1C3-activated Prodrug OBI-3424
23 Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia Not yet recruiting NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
24 A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens. Terminated NCT00419081 Phase 2 Forodesine Hydrochloride Sterile Solution, 5 mg/mL;Forodesine Hydrochloride Capsules (100 mg)
25 A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC Terminated NCT00981799 Phase 1, Phase 2 Nelarabine;Etoposide;Cyclophosphamide;Methotrexate;Filgrastim
26 Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL) Terminated NCT02999633 Phase 2 Isatuximab SAR650984;dexamethasone;dexamethasone;acetaminophen;ranitidine;diphenhydramine
27 A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated NCT02518750 Phase 2 Dexamethasone;Panobinostat;Liposomal vincristine;Mitoxantrone;Peg-asparaginase;Bortezomib;Intrathecal Triples;High-dose methotrexate;6-Mercaptopurine;High-dose cytarabine;Nelarabine;Cyclophosphamide;Etoposide;Clofarabine
28 An Open-label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) Withdrawn NCT03207542 Phase 2 Daratumumab
29 Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed NCT01363817 Phase 1 BMS-906024;Dexamethasone
30 A PHASE I TRIAL OF PF-03084014 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCY AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA Completed NCT00878189 Phase 1 PF-03084014
31 Clinical Evaluation of 506U78 in Japanese Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma. Completed NCT00406757 Phase 1 Nelarabine injection 400mg/m2;Nelarabine injection 650mg/m2;Nelarabine injection 1000mg/m2;Nelarabine injection 1500mg/m2
32 A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies Completed NCT01094860 Phase 1 Nelarabine
33 Aflac LL1602 ENCERT: A Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Relapsed T Cell Lymphoblastic Leukemia/Lymphoma Recruiting NCT03328104 Phase 1 Everolimus;Nelarabine;Cyclophosphamide;Etoposide
34 Phase 1 Therapy of Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen Recruiting NCT03081910 Phase 1 Fludarabine;Cytoxan
35 Cell Therapy for High Risk T-Cell Malignancies Using CD7-specific CAR Expressed On Autologous T Cells (CRIMSON) Not yet recruiting NCT03690011 Phase 1 Fludarabine;Cytoxan
36 A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma Terminated NCT00100152 Phase 1 MK0752, (Notch Inhibitor)
37 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
38 The Effect of Chemotherapy on Regulatory T Cells in Children With Acute Lymphoblastic Leukemia Unknown status NCT03413046
39 Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia Unknown status NCT00343369 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisolone;teniposide;thioguanine;vincristine sulfate
40 Molecular Taxonomy in Pediatric Cancer- IncRNA Expression in Primary T-ALL Completed NCT01626183
41 Four Years Experience With Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden. Population-based Data. Completed NCT01950286
42 Molecular Mechanisms of NOTCH Induced Transformation in T-ALL Completed NCT00899366
43 Metabolic Pathways in T-Cell Acute Lymphoblastic Leukemia (T-ALL) Completed NCT01581528
44 Biological Correlates With T-cell Acute Lymphoblastic Leukemia (T-ALL) Gene Expression and Clinical Outcome Completed NCT01295476
45 Signaling in Tumorigenesis and Immunity Completed NCT01520246
46 Compound 506U78 (NSC 686673) in Patients With Relapsed or Refractory T-Cell ALL or T-Cell Lymphoblastic Lymphoma Completed NCT00003837 nelarabine
47 Molecular Correlates of Methotrexate in Childhood ALL Completed NCT00898404
48 Treatment for Newly Diagnosed Patients With Stage III/IV Non-Hodgkin Lymphoma-Study XIII (A Therapeutic Pilot Study) Completed NCT00187122 Vincristine;Daunomycin;L-Asparaginase;Cytarabine;Methotrexate;Mercaptopurine;Etoposide;Cyclophosphamide;Prednisone;Dexamethasone
49 The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia Completed NCT00016302 prednisone;vincristine sulfate;daunorubicin hydrochloride;asparaginase;methotrexate;cyclophosphamide;cytarabine;mercaptopurine;leucovorin calcium;dexamethasone;doxorubicin hydrochloride;thioguanine;nelarabine;pegaspargase
50 Translational Research - Observational Study for Identification of New Possible Prognostic Factors and Future Therapeutic Targets in Children With Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT01185886

Search NIH Clinical Center for T-Cell Acute Lymphoblastic Leukemia

Genetic Tests for T-Cell Acute Lymphoblastic Leukemia

Genetic tests related to T-Cell Acute Lymphoblastic Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Acute Lymphoblastic Leukemia 29

Anatomical Context for T-Cell Acute Lymphoblastic Leukemia

MalaCards organs/tissues related to T-Cell Acute Lymphoblastic Leukemia:

40
T Cells, Myeloid, B Cells, Bone, Bone Marrow, Brain, Lung

Publications for T-Cell Acute Lymphoblastic Leukemia

Articles related to T-Cell Acute Lymphoblastic Leukemia:

(show top 50) (show all 2068)
# Title Authors PMID Year
1
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
2
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. 6
9531611 1998
3
Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation. 61
31906810 2020
4
COTI-2 induces cell apoptosis in pediatric acute lymphoblastic leukemia via upregulation of miR-203. 61
32063077 2020
5
Rho guanosine nucleotide exchange factors are not such bad guys after all in cancera. 61
29313423 2020
6
Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. 61
31537687 2020
7
CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study. 61
32492289 2020
8
Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. 61
31822778 2020
9
Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways. 61
32479694 2020
10
Bilateral optic nerve and retinal infiltration as an initial site of relapse in a child with T-cell acute lymphoblastic leukemia. 61
32368688 2020
11
Haploidentical stem cells combined with a small dose of umbilical cord blood transplantation exert similar survival outcome of HLA-matched stem cells transplantation in T-cell acute lymphoblastic leukemia. 61
31488878 2020
12
Sending CAR T Cells after T-cell Malignancies. 61
32349973 2020
13
Mucorales DNA detection in serum specimens for early diagnosis of mucormycosis. 61
32156450 2020
14
Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia. 61
32181817 2020
15
Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. 61
31904116 2020
16
Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells. 61
32277947 2020
17
Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells. 61
31962201 2020
18
Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. 61
32501545 2020
19
Preclinical Efficacy of Humanized, non-FcγR Binding Anti-CD3 Antibodies in T-cell Acute Lymphoblastic Leukemia. 61
32483610 2020
20
Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF-κB Pathways. 61
32487610 2020
21
MiR-29b-3p cooperates with miR-29c-3p to affect the malignant biological behaviors in T-cell acute lymphoblastic leukemia via TFAP2C/GPX1 axis. 61
32423796 2020
22
The Clinical and Molecular Characteristics of FLT3 Mutations in Chinese De Novo Adolescent and Adult Acute Lymphoblastic Leukemia Patients. 61
32173273 2020
23
Aggressive Langerhans cell histiocytosis transformation of T cell acute lymphoblastic leukemia detected on 18F-FDG PET/CT. 61
32504290 2020
24
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. 61
32386594 2020
25
A Novel Flow Cytometric Assay to Identify Inhibitors of RBPJ-DNA Interactions. 61
32567455 2020
26
[Dihydroartemisinin Induces Apoptosis of Human Acute T Lymphocytic Leukemia Cells by Activating Oxidative Stress]. 61
32552932 2020
27
JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. 61
32530039 2020
28
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. 61
32439800 2020
29
Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism. 61
32540572 2020
30
Secondary histiocytic sarcoma with BRAFV600E mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib. 61
32037654 2020
31
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. 61
31926364 2020
32
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. 61
32315407 2020
33
Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia. 61
32142900 2020
34
Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL. 61
31772299 2020
35
Posttranslational regulation of the exon skipping machinery controls aberrant splicing in leukemia. 61
32444465 2020
36
WNT7A Expression is Downregulated in T Lymphocytes after T-Cell Receptor Activation Due to Histone Modifications and in T-ALL by DNA Methylation. 61
32458062 2020
37
Antiproliferative effects of chalcones on T cell acute lymphoblastic leukemia-derived cells: Role of PKCβ. 61
32394529 2020
38
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. 61
32468488 2020
39
PTEN and AKT1 Variations in Childhood T-Cell Acute Lymphoblastic Leukemia 61
31744268 2020
40
Oncorequisite role of an aldehyde dehydrogenase in the pathogenesis of T-cell acute lymphoblastic leukemia. 61
32414855 2020
41
TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. 61
32409690 2020
42
LINC00511 exacerbated T-cell acute lymphoblastic leukemia via miR-195-5p/LRRK1 axis. 61
32242897 2020
43
Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts. 61
31467126 2020
44
SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. 61
32382081 2020
45
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. 61
32146726 2020
46
Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support. 61
32471246 2020
47
hsa-miR-20b-5p and hsa-miR-363-3p Affect Expression of PTEN and BIM Tumor Suppressor Genes and Modulate Survival of T-ALL Cells In Vitro. 61
32380791 2020
48
Highly Sensitive Minimal Residual Disease Detection by Biomimetic Multivalent Aptamer Nanoclimber Functionalized Microfluidic Chip. 61
32323494 2020
49
MAML1-Dependent Notch-Responsive Genes Exhibit Differing Cofactor Requirements for Transcriptional Activation. 61
32179552 2020
50
EZH2-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress. 61
32349972 2020

Variations for T-Cell Acute Lymphoblastic Leukemia

ClinVar genetic disease variations for T-Cell Acute Lymphoblastic Leukemia:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ABL1 Translocation Pathogenic 617566 9:133709770-133709771
2 BCL10 NM_003921.5(BCL10):c.136dup (p.Ile46fs)duplication Pathogenic 6259 rs387906351 1:85736510-85736511 1:85270827-85270828
3 BAX NM_138761.4(BAX):c.199G>A (p.Gly67Arg)SNV Pathogenic 9513 rs398122513 19:49459056-49459056 19:48955799-48955799
4 BAX NM_138761.4(BAX):c.115_121del (p.Gly39fs)deletion Pathogenic 9514 rs398122840 19:49458971-49458977 19:48955714-48955720

Copy number variations for T-Cell Acute Lymphoblastic Leukemia from CNVD:

7 (show top 50) (show all 91)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21835 1 16200000 23900000 Copy number CHD5 T-cell acute lymphoblastic leukemia
2 21836 1 16200000 23900000 Copy number HES2 T-cell acute lymphoblastic leukemia
3 21837 1 16200000 23900000 Copy number HES3 T-cell acute lymphoblastic leukemia
4 32217 1 34600000 44100000 Copy number T-cell acute lymphoblastic leukemia
5 34248 1 5400000 7200000 Deletion T-cell acute lymphoblastic leukemia
6 38166 10 1 3800000 Copy number T-cell acute lymphoblastic leukemia
7 41844 10 24600000 31300000 Copy number ADARB2 T-cell acute lymphoblastic leukemia
8 41845 10 24600000 31300000 Copy number PFKP T-cell acute lymphoblastic leukemia
9 41846 10 24600000 31300000 Copy number PITRM1 T-cell acute lymphoblastic leukemia
10 41847 10 24600000 31300000 Copy number WDR37 T-cell acute lymphoblastic leukemia
11 46873 10 87900000 92900000 Loss PTEN T-cell acute lymphoblastic leukemia
12 48336 11 1 2800000 Gain IGF2 T-cell acute lymphoblastic leukemia
13 48337 11 1 2800000 Gain hsa-mir-675 T-cell acute lymphoblastic leukemia
14 48490 11 1 52900000 Duplication T-cell acute lymphoblastic leukemia
15 53563 11 31000000 36400000 Copy number WT1 T-cell acute lymphoblastic leukemia
16 57103 11 63100000 67100000 Gain MAP4K2 T-cell acute lymphoblastic leukemia
17 57104 11 63100000 67100000 Gain RASGRP2 T-cell acute lymphoblastic leukemia
18 60336 11 85300000 87900000 Loss PICALM T-cell acute lymphoblastic leukemia
19 60878 11 92800000 110400000 Copy number ATM T-cell acute lymphoblastic leukemia
20 61471 12 1 14800000 Deletion T-cell acute lymphoblastic leukemia
21 61531 12 1 35400000 Duplication T-cell acute lymphoblastic leukemia
22 61611 12 10000000 12600000 Loss CDKN1B T-cell acute lymphoblastic leukemia
23 61613 12 10000000 12600000 Loss hsa-mir-614 T-cell acute lymphoblastic leukemia
24 61779 12 10100000 14800000 Copy number CDKN1B T-cell acute lymphoblastic leukemia
25 74382 13 105800000 109100000 Gain TNFSF13B T-cell acute lymphoblastic leukemia
26 78375 13 50900000 55300000 Deletion DLEU7 T-cell acute lymphoblastic leukemia
27 78376 13 50900000 55300000 Deletion KCNRG T-cell acute lymphoblastic leukemia
28 82826 14 15600000 23600000 Deletion T-cell acute lymphoblastic leukemia
29 88309 6 135544145 135582003 Copy number MYB T-cell acute lymphoblastic leukemia
30 104069 16 66700000 70800000 Deletion CTCF T-cell acute lymphoblastic leukemia
31 108732 17 22200000 28800000 Duplication T-cell acute lymphoblastic leukemia
32 109390 17 25800000 31800000 Copy number NF1 T-cell acute lymphoblastic leukemia
33 109749 17 28800000 35400000 Deletion T-cell acute lymphoblastic leukemia
34 111430 17 3600000 6800000 Loss NALP1 T-cell acute lymphoblastic leukemia
35 115247 17 55600000 58400000 Gain MSI2 T-cell acute lymphoblastic leukemia
36 115248 17 55600000 58400000 Gain VEZF1 T-cell acute lymphoblastic leukemia
37 115617 17 58400000 59900000 Gain MAP3K3 T-cell acute lymphoblastic leukemia
38 115618 17 58400000 59900000 Gain SMURF2 T-cell acute lymphoblastic leukemia
39 115619 17 58400000 59900000 Gain hsa-mir-633 T-cell acute lymphoblastic leukemia
40 115878 17 59900000 64600000 Gain PRKCA T-cell acute lymphoblastic leukemia
41 116600 17 68400000 72200000 Gain GPR142 T-cell acute lymphoblastic leukemia
42 116601 17 68400000 72200000 Gain GPRC5C T-cell acute lymphoblastic leukemia
43 121278 18 41800000 46400000 Loss SMAD4 T-cell acute lymphoblastic leukemia
44 124174 19 1 6900000 Gain MKNK2 T-cell acute lymphoblastic leukemia
45 131214 19 53800000 57600000 Gain FUT2 T-cell acute lymphoblastic leukemia
46 131215 19 53800000 57600000 Gain RASIP1 T-cell acute lymphoblastic leukemia
47 133723 19 6900000 12600000 Gain INSR T-cell acute lymphoblastic leukemia
48 133733 19 6900000 13900000 Deletion T-cell acute lymphoblastic leukemia
49 140125 2 19200000 27900000 Copy number NCOA1 T-cell acute lymphoblastic leukemia
50 140126 2 19200000 27900000 Copy number TP53I3 T-cell acute lymphoblastic leukemia

Expression for T-Cell Acute Lymphoblastic Leukemia

Search GEO for disease gene expression data for T-Cell Acute Lymphoblastic Leukemia.

Pathways for T-Cell Acute Lymphoblastic Leukemia

Pathways related to T-Cell Acute Lymphoblastic Leukemia according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for T-Cell Acute Lymphoblastic Leukemia

Cellular components related to T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.5 TLX3 TLX1 TAL2 TAL1 OLIG2 NUP98
2 nuclear chromatin GO:0000790 9.43 TLX3 TLX1 TAL2 TAL1 OLIG2 LYL1

Biological processes related to T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10 TLX3 TLX1 TAL2 TAL1 NOTCH1 LYL1
2 viral process GO:0016032 9.96 TSPAN7 NUP98 LCK FBXW7 BAX
3 regulation of apoptotic process GO:0042981 9.85 BCL10 BAX ATM ABL1
4 positive regulation of apoptotic process GO:0043065 9.83 NOTCH1 BCL10 BAX ATM ABL1
5 regulation of cell proliferation GO:0042127 9.81 TAL1 NOTCH1 LCK ABL1
6 negative regulation of neuron differentiation GO:0045665 9.63 TLX3 OLIG2 NOTCH1
7 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.58 BAX ATM ABL1
8 definitive hemopoiesis GO:0060216 9.57 TAL1 LYL1
9 post-embryonic development GO:0009791 9.56 TAL2 BAX ATM ABL1
10 thalamus development GO:0021794 9.54 TAL2 OLIG2
11 DNA damage induced protein phosphorylation GO:0006975 9.49 ATM ABL1
12 B cell apoptotic process GO:0001783 9.48 BCL10 BAX
13 regulation of hematopoietic stem cell differentiation GO:1902036 9.46 TAL1 LMO2 LMO1 ABL1
14 apoptotic process involved in embryonic digit morphogenesis GO:1902263 9.37 NOTCH1 BAX
15 neuron differentiation GO:0030182 9.35 TLX3 TAL1 OLIG2 NOTCH1 ABL1
16 regulation of T cell homeostatic proliferation GO:0046013 9.32 LMO1 IL2
17 positive regulation of transcription by RNA polymerase II GO:0045944 9.28 TLX3 TLX1 TAL1 NOTCH1 LMO2 LMO1

Molecular functions related to T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein dimerization activity GO:0046983 9.26 TAL2 TAL1 OLIG2 LYL1
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.17 TLX3 TLX1 TAL2 TAL1 OLIG2 LYL1
3 kinase activator activity GO:0019209 9.16 IL2 BCL10

Sources for T-Cell Acute Lymphoblastic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....